US EditionLarotrectinib discontinuation possible for some paediatric NTRK fusion-positive tumours
Summary by Institut-servier.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Larotrectinib discontinuation possible for some paediatric NTRK fusion-positive tumours
By Lynda Williams, medwireNews ReportermedwireNews: Children who respond to larotrectinib therapy for sarcoma with a neurotrophic tyrosine receptor kinase gene fusion may be able to discontinue treatment, indicates research published in the Journal of Clinical Oncology.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full story on the L’Institut Servier websiteImage credit: © Fa…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
